Moreover, a recent study in melanoma suggests that ornidazole could play a role in suppressing CD133+ stem cells [71], and CD133+ is commonly expressed in NSCLC [72,73], and be a potential novel target [74,75]. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.